Lilly Oritavancin Antibacterial Agent NDA Submission Targeted For 2003

Lilly expects to file an NDA for the antibacterial glycopeptide oritavancin by 2003, Senior VP-Pharmaceutical Products John Lechleiter, PhD, told the J.P. Morgan H&Q Healthcare Conference in San Francisco Jan. 8.